Syed Muhammad Tayab, Shaima Yasmeen, Amna Noor
Objective: The purpose of this study is to interrogate the safety and effectiveness of dapagliflozin in the patients suffering from diabetes who are already using high insulin doses. Methodology: This research work carried out in DHQ Teaching Hospital, Sahiwal. In this research work, 30 patients of diabetes who were getting high insulin doses (>0.50U/kg) and oral anti-diabetic therapy except SGLT-2 inhibitors were the participants of this research work. Primary endpoint of this research work was alteration in the level of HbA1c, doses of insulin and electrolyte from the addition of the dapagliflozin 10.0mg to a week. Results: After the completion of 3 months, there was obvious decrease in the body mass index from 33.31±4.51 to the 32.14±4.66 (P=0.0010). We also observed the reduction in the requirement of insulin from 76.0 ±23.15 U/kg to 57.6± 17.61 U /kg (P<0.0010). There was also decrease in the levels of HbA1c (Δ1.60%) and fasting blood glucose (Δ68.60mg/dl) (P<0.0010). Among the levels of serum electrolyte, a slight butmeaningful rise of the levels of BUN (Blood Urea Nitrogen) and Na (Sodium) were observed (P= 0.0440 and P= 0.0260). We found no significant alterations in the levels of serum cholesterol with electrolytes like Vitamin-D, potassium, magnesium, calcium, and phosphorus (P>0.050). Conclusion: In the patients of diabetes mellitus with incompetently controlled regulations of glucose regardless of the treatment with high insulin doses, dapagliflozin may be a substitute combination option to reduce the requirement of insulin doses and get optimal level of HbA1c, levels of fasting plasma glucose as well as BMI without any important side effect. KEYWORDS: Effectiveness, reduction, dapagliflozin, magnesium, cholesterol, therapy, insulin, doses, HbA1c.